Coenzyme Q10 (CoQ10), also known as ubiquinone, is named for its chemical structure. The “Q” refers to its quinone group, and the “10” reflects the ten isoprene units in its side chain. CoQ10 is present in all mammalian—and more broadly, all eukaryotic—cells. Within the cell, it is found primarily in the mitochondria, where it plays a central role in the electron transport chain and cellular energy production. Tissues with high energy demands, such as the heart, liver, and kidneys, contain particularly high concentrations of CoQ10. In addition to its role in energy metabolism, CoQ10 is fat-soluble and functions as an antioxidant.
Because of its role in mitochondrial energy production, CoQ10 became an early area of interest in heart failure research. A double-blind, placebo-controlled study published in the European Heart Journal (November 2006; 27(22):2675–2681) evaluated 23 patients with stable, chronic heart failure using a four-phase crossover design. Participants received CoQ10 supplementation, CoQ10 combined with supervised exercise, placebo alone, and placebo combined with exercise. The investigators reported changes in vascular dilation, left ventricular contractility, and overall functional capacity during the CoQ10 phases, with exercise appearing to augment these effects. The authors noted that these findings were consistent with earlier observations.
Earlier work had already explored CoQ10 in this population. Research published in BioFactors (2006; 25(1–4):137–145) and in the Am J Clin Nutr. 2013;97:268–275 reviewed clinical and mechanistic studies examining CoQ10 in patients with heart failure, focusing on myocardial energy metabolism and functional measures.
One of the earlier clinical studies, published in Clinical Investigator (1993; 71:S145–S149), reported that over a three-month period, 54% of patients receiving CoQ10 supplementation (50–150 mg per day) showed changes in at least three heart failure–related symptoms. Reported changes included cyanosis, edema, shortness of breath, arrhythmias, and vertigo. Observational research from this period also suggested that lower CoQ10 levels were more commonly found in patients with more severe symptoms, as described in the International Journal of Tissue Reactions (1990; 12(3):155–162).
Taken together, these studies reflect early investigative efforts into the role of CoQ10 and mitochondrial energy metabolism in heart failure. They helped shape subsequent research questions and provided historical context for later, larger studies conducted alongside modern heart-failure therapies.
